Lv65
2760 积分 2022-08-25 加入
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
10天前
已完结
Dual-target EZH2 inhibitor: latest advances in medicinal chemistry
14天前
已完结
EP-0108A is a moderation selectively BRD4 BD2 inhibitor with potential AML tumor suppression
24天前
已关闭
A patent review of BRD4 inhibitors (2020-present)
27天前
已完结
Dietary control of peripheral adipose storage capacity through membrane lipid remodelling
28天前
已完结
BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage
1个月前
已完结
EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes
1个月前
已完结
Epigenetic Cooperativity as a Therapeutic Vulnerability in Cancer
1个月前
已完结
Design, synthesis and mechanism studies of dual EZH2/BRD4 inhibitors for cancer therapy
1个月前
已完结
BCL6 promotes a stem-like CD8 + T cell program in cancer via antagonizing BLIMP1
1个月前
已完结
皖公网安备34019202002308
